Literature DB >> 10471633

Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings.

J K Choi1, J Kearns, H I Palevsky, K T Montone, L R Kaiser, C M Zmijewski, J E Tomaszewski.   

Abstract

The clinical and pathologic findings seen in hyperacute rejection are well documented in renal and cardiac allografts. We describe the second case of hyperacute rejection in a pulmonary allograft and detail the immediate clinicopathologic findings. The patient underwent a single lung transplant for severe COPD with postoperative course complicated by acute rejection and graft failure. Eleven days later, the patient underwent a second transplant with intra-operative course complicated by rapid pulmonary edema and copious production of frothy, pink fluid from the bronchial orifice of the allograft followed by death within four hours of anastomoses. Intraoperative biopsy and autopsy demonstrated platelet/fibrin thrombi, marked interstitial neutrophilia, alveolar edema, and antibody deposition on the endothelial surface and vasculature walls. Prior to the first transplant, the patient's serum had 0% panel reactive antibody and was crossmatch compatible with the first allograft. The patient's serum prior to the second transplant contained cross-reacting antibodies to the donor's B and T lymphocytes. The immediate clinical findings in this case are similar to the findings in a previously reported case. This report is the first documentation of the immediate pathologic features of hyperacute rejection in a lung allograft which are similar to those seen with other organ allografts.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471633     DOI: 10.1164/ajrccm.160.3.9706115

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  9 in total

1.  Antibody-mediated Rejection in Lung Transplantation.

Authors:  Hrishikesh S Kulkarni; Bradford C Bemiss; Ramsey R Hachem
Journal:  Curr Transplant Rep       Date:  2015-09-30

2.  Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study.

Authors:  Ramsey R Hachem; Malek Kamoun; Marie M Budev; Medhat Askar; Vivek N Ahya; James C Lee; Deborah J Levine; Marilyn S Pollack; Gundeep S Dhillon; David Weill; Kenneth B Schechtman; Lorriana E Leard; Jeffrey A Golden; LeeAnn Baxter-Lowe; Thalachallour Mohanakumar; Dolly B Tyan; Roger D Yusen
Journal:  Am J Transplant       Date:  2018-05-15       Impact factor: 8.086

Review 3.  Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation.

Authors:  S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2013-07-02       Impact factor: 3.119

4.  Antibody-Mediated Lung Transplant Rejection.

Authors:  Ramsey Hachem
Journal:  Curr Respir Care Rep       Date:  2012-09

5.  Pre-transplant Panel Reactive Antibody and Survival in Adult Cystic Fibrosis Patients After Lung Transplantation.

Authors:  Don Hayes; Dmitry Tumin; Joseph D Tobias
Journal:  Lung       Date:  2016-03-02       Impact factor: 2.584

6.  Antibody desensitization therapy in highly sensitized lung transplant candidates.

Authors:  L D Snyder; A L Gray; J M Reynolds; G M Arepally; A Bedoya; M G Hartwig; R D Davis; K E Lopes; W E Wegner; D F Chen; S M Palmer
Journal:  Am J Transplant       Date:  2014-02-19       Impact factor: 8.086

Review 7.  Ectonucleotidases in solid organ and allogeneic hematopoietic cell transplantation.

Authors:  Petya Chernogorova; Robert Zeiser
Journal:  J Biomed Biotechnol       Date:  2012-10-16

Review 8.  Critical care management of the lung transplant recipient.

Authors:  James C Lee; Joshua M Diamond; Jason D Christie
Journal:  Curr Respir Care Rep       Date:  2012-06-22

9.  Imaging indications and findings in evaluation of lung transplant graft dysfunction and rejection.

Authors:  Mnahi Bin Saeedan; Sanjay Mukhopadhyay; C Randall Lane; Rahul D Renapurkar
Journal:  Insights Imaging       Date:  2020-01-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.